Association of serum Rituximab (IDEC–C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin’s lymphoma-Reference-Cited by-同舟云学术

Association of serum Rituximab (IDEC–C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin’s lymphoma

Published:1998-09 Issue:9 Volume:9 Page:995-1001
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Berinstein N.L.,Grillo-López A.J.,White C.A.,Bence-Bruckler I.,Maloney D.,Czuczman M.,Green D.,Rosenberg J.,McLaughlin P.,Shen D.

Publisher

Elsevier BV

Subject

Oncology,Hematology

Link

http://academic.oup.com/annonc/article-pdf/9/9/995/19482128/9-9-995.pdf

Reference27 articles.

1. Dillman R. Antibodies as cytotoxic therapy. J Clin Oncol 119; 12: 1497–515.

2. A clinical trial of anti-idiotype therapy for B cell malignancy;Meeker;Blood,1985

3. Treatment of B-cell lymphomas with anti-idiotype antibodies alone and in combination with alpha interferon;Brown;Blood,1989

4. Monoclonal anti-idiotype antibody therapy of B-cell lymphoma: The addition of a short course of chemotherapy does not interfere with the antitumor effect nor prevent the emergence of idiotype-negative variant cells;Maloney;Blood,1992

5. Immunosuppressive toxicity of CAMPATH 1H monoclonal antibody in the treatment of patients with recurrent low grade lymphoma;Tang;Leuk Lymph,1996

Cited by 480 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Therapeutic drug monitoring of immunotherapies with novel Affimer–NanoBiT sensor construct;Sensors & Diagnostics;2024

2. Anti-CD20 antibody treatment for B-cell malignancies;Resistance to Anti-Cd20 Antibodies and Approaches for their Reversal;2024

3. Mechanisms of resistance to anti-CD20 antibodies in lymphoid malignancies;Resistance to Anti-Cd20 Antibodies and Approaches for their Reversal;2024

4. Antibody-Based Biotherapeutics in Cancer;Pharmaceutical Biotechnology;2024

5. Optimization of Rituximab Therapy in Adult Patients With PLA2R1-Associated Membranous Nephropathy With Artificial Intelligence;Kidney International Reports;2024-01